These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24147022)

  • 1. Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
    Muthuswami M; Ramesh V; Banerjee S; Viveka Thangaraj S; Periasamy J; Bhaskar Rao D; Barnabas GD; Raghavan S; Ganesan K
    PLoS One; 2013; 8(10):e77553. PubMed ID: 24147022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
    Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.
    Mesquita B; Lopes P; Rodrigues A; Pereira D; Afonso M; Leal C; Henrique R; Lind GE; Jerónimo C; Lothe RA; Teixeira MR
    Breast Cancer Res Treat; 2013 Feb; 138(1):37-45. PubMed ID: 23329352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
    Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
    Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin receptor expression and cell signaling in breast cancer.
    Frankenberry KA; Skinner H; Somasundar P; McFadden DW; Vona-Davis LC
    Int J Oncol; 2006 Apr; 28(4):985-93. PubMed ID: 16525650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
    Shats I; Gatza ML; Liu B; Angus SP; You L; Nevins JR
    Cancer Res; 2013 Oct; 73(19):6056-67. PubMed ID: 23966291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells.
    Kurrle N; Ockenga W; Meister M; Völlner F; Kühne S; John BA; Banning A; Tikkanen R
    BMC Cancer; 2013 Dec; 13():575. PubMed ID: 24304721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer.
    Vangamudi B; Peng DF; Cai Q; El-Rifai W; Zheng W; Belkhiri A
    Mol Cancer; 2010 Sep; 9():240. PubMed ID: 20836878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
    Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG
    Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
    Wells V; Mallucci L
    Breast Cancer Res; 2009; 11(1):R2. PubMed ID: 19133120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
    Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
    Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.